ELDN (Eledon Pharmaceuticals) 12-1 Month Momentum % : 205.00% (As of Dec. 14, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Eledon Pharmaceuticals 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-12-14), Eledon Pharmaceuticals's 12-1 Month Momentum % is 205.00%.

The industry rank for Eledon Pharmaceuticals's 12-1 Month Momentum % or its related term are showing as below:

ELDN's 12-1 Month Momentum % is ranked better than
96.27% of 1447 companies
in the Biotechnology industry
Industry Median: -15.46 vs ELDN: 205.00

Competitive Comparison of Eledon Pharmaceuticals's 12-1 Month Momentum %

For the Biotechnology subindustry, Eledon Pharmaceuticals's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eledon Pharmaceuticals's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eledon Pharmaceuticals's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Eledon Pharmaceuticals's 12-1 Month Momentum % falls into.

Eledon Pharmaceuticals (NAS:ELDN) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eledon Pharmaceuticals (NAS:ELDN) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Eledon Pharmaceuticals 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Eledon Pharmaceuticals's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Eledon Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eledon Pharmaceuticals Inc (NAS:ELDN) » Definitions » 12-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

2TK:Germany

Address

19900 MacArthur Boulevard, Suite 550, Irvine, CA, USA, 92612

Website

https://www.eledon.com

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Executives

Allan Kirk	director	C/O ELEDON PHARMACEUTICALS, INC., 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Robinson James A. Jr.	director	852 WINTER STREET, WALTHAM MA 02451
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Steven Perrin	director, officer: See Remarks	C/O ANELIXIS THERAPEUTICS, INC., 1500 DISTRICT AVENUE, BURLINGTON MA 01803
David-alexandre C Gros	director, officer: Chief Executive Officer	220 MARLBOROUGH STREET, #6, BOSTON MA 02116
Jan Hillson	director	C/O ELEDON PHARMACEUTICALS, INC., 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Paul Sean Little	officer: CHIEF FINANCIAL OFFICER	SIENTRA, INC., 420 SOUTH FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Bryan E. Smith	officer: See Remarks	C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
June Lee	director	C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Orbimed Israel Biofund Gp Limited Partnership	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
Logos Global Management Lp	10 percent owner	1 LETTERMAN DRIVE, BLDG C, SUITE C3-350, SAN FRANCISCO CA 94129
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104